chartexchange

Coya Therapeutics Reports Q3 Revenue of $0.23 Million, Net Loss of $10. ...

GuruFocus | Nov 10, 2026 10:00 AM EST

Enrollment Completion of Phase 2/3 ALSTARS Trial Anchors a Quarter Marked by Higher R&D Spending and a $35.8 Million Cash Position Related Stocks: COYA ,

Read original article